Adenoviral vector-mediated RTVP-1 gene-modified tumor cell-based vaccine suppresses the development of experimental prostate cancer

K. Naruishi, T. L. Timme, N. Kusaka, T. Fujita, G. Yang, A. Goltsov, T. Satoh, X. Ji, W. Tian, E. Abdelfattah, T. Men, Masami Watanabe, K. Tabata, T. C. Thompson

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

We previously identified a novel p53 target gene, RTVP-1, that possesses unique cytotoxic and immunostimulatory activities which make it potentially useful for cancer gene therapy. To test the therapeutic potential of RTVP-1 in a gene-modified tumor cell-based vaccine model, we used an adenoviral vector capable of efficient transduction and expression of RTVP-1 (AdRTVP-1), together with a highly metastatic mouse prostate cancer cell line (178-2 BMA). A vaccine was prepared with 178-2 BMA cells transduced with AdRTVP-1 or a control adenoviral vector expressing β-galactosidase (Adβgal). After irradiation of the cells, syngeneic 129/Sv mice were vaccinated three times at weekly intervals. After 3 weeks, they were challenged with orthotopic 178-2 BMA cells. After 21 days, fewer than 60% of the RTVP-1-cell-vaccinated mice developed tumors compared to 100% of the control mice. The RTVP-1-cell vaccine significantly reduced primary tumor wet weight compared with control Adβgal-cell vaccine (P

Original languageEnglish
Pages (from-to)658-663
Number of pages6
JournalCancer Gene Therapy
Volume13
Issue number7
DOIs
Publication statusPublished - Jul 17 2006
Externally publishedYes

Fingerprint

Prostatic Neoplasms
Vaccines
Genes
Neoplasms
129 Strain Mouse
Galactosidases
Neoplasm Genes
p53 Genes
Tumor Burden
Genetic Therapy
Cell Line

Keywords

  • Immunotherapy
  • Orthotopic
  • Prostate cancer
  • RTVP-1
  • Vaccine

ASJC Scopus subject areas

  • Cancer Research
  • Genetics

Cite this

Adenoviral vector-mediated RTVP-1 gene-modified tumor cell-based vaccine suppresses the development of experimental prostate cancer. / Naruishi, K.; Timme, T. L.; Kusaka, N.; Fujita, T.; Yang, G.; Goltsov, A.; Satoh, T.; Ji, X.; Tian, W.; Abdelfattah, E.; Men, T.; Watanabe, Masami; Tabata, K.; Thompson, T. C.

In: Cancer Gene Therapy, Vol. 13, No. 7, 17.07.2006, p. 658-663.

Research output: Contribution to journalArticle

Naruishi, K, Timme, TL, Kusaka, N, Fujita, T, Yang, G, Goltsov, A, Satoh, T, Ji, X, Tian, W, Abdelfattah, E, Men, T, Watanabe, M, Tabata, K & Thompson, TC 2006, 'Adenoviral vector-mediated RTVP-1 gene-modified tumor cell-based vaccine suppresses the development of experimental prostate cancer', Cancer Gene Therapy, vol. 13, no. 7, pp. 658-663. https://doi.org/10.1038/sj.cgt.7700919
Naruishi, K. ; Timme, T. L. ; Kusaka, N. ; Fujita, T. ; Yang, G. ; Goltsov, A. ; Satoh, T. ; Ji, X. ; Tian, W. ; Abdelfattah, E. ; Men, T. ; Watanabe, Masami ; Tabata, K. ; Thompson, T. C. / Adenoviral vector-mediated RTVP-1 gene-modified tumor cell-based vaccine suppresses the development of experimental prostate cancer. In: Cancer Gene Therapy. 2006 ; Vol. 13, No. 7. pp. 658-663.
@article{3683dfbb86354bc284ebe890974e0f63,
title = "Adenoviral vector-mediated RTVP-1 gene-modified tumor cell-based vaccine suppresses the development of experimental prostate cancer",
abstract = "We previously identified a novel p53 target gene, RTVP-1, that possesses unique cytotoxic and immunostimulatory activities which make it potentially useful for cancer gene therapy. To test the therapeutic potential of RTVP-1 in a gene-modified tumor cell-based vaccine model, we used an adenoviral vector capable of efficient transduction and expression of RTVP-1 (AdRTVP-1), together with a highly metastatic mouse prostate cancer cell line (178-2 BMA). A vaccine was prepared with 178-2 BMA cells transduced with AdRTVP-1 or a control adenoviral vector expressing β-galactosidase (Adβgal). After irradiation of the cells, syngeneic 129/Sv mice were vaccinated three times at weekly intervals. After 3 weeks, they were challenged with orthotopic 178-2 BMA cells. After 21 days, fewer than 60{\%} of the RTVP-1-cell-vaccinated mice developed tumors compared to 100{\%} of the control mice. The RTVP-1-cell vaccine significantly reduced primary tumor wet weight compared with control Adβgal-cell vaccine (P",
keywords = "Immunotherapy, Orthotopic, Prostate cancer, RTVP-1, Vaccine",
author = "K. Naruishi and Timme, {T. L.} and N. Kusaka and T. Fujita and G. Yang and A. Goltsov and T. Satoh and X. Ji and W. Tian and E. Abdelfattah and T. Men and Masami Watanabe and K. Tabata and Thompson, {T. C.}",
year = "2006",
month = "7",
day = "17",
doi = "10.1038/sj.cgt.7700919",
language = "English",
volume = "13",
pages = "658--663",
journal = "Cancer Gene Therapy",
issn = "0929-1903",
publisher = "Nature Publishing Group",
number = "7",

}

TY - JOUR

T1 - Adenoviral vector-mediated RTVP-1 gene-modified tumor cell-based vaccine suppresses the development of experimental prostate cancer

AU - Naruishi, K.

AU - Timme, T. L.

AU - Kusaka, N.

AU - Fujita, T.

AU - Yang, G.

AU - Goltsov, A.

AU - Satoh, T.

AU - Ji, X.

AU - Tian, W.

AU - Abdelfattah, E.

AU - Men, T.

AU - Watanabe, Masami

AU - Tabata, K.

AU - Thompson, T. C.

PY - 2006/7/17

Y1 - 2006/7/17

N2 - We previously identified a novel p53 target gene, RTVP-1, that possesses unique cytotoxic and immunostimulatory activities which make it potentially useful for cancer gene therapy. To test the therapeutic potential of RTVP-1 in a gene-modified tumor cell-based vaccine model, we used an adenoviral vector capable of efficient transduction and expression of RTVP-1 (AdRTVP-1), together with a highly metastatic mouse prostate cancer cell line (178-2 BMA). A vaccine was prepared with 178-2 BMA cells transduced with AdRTVP-1 or a control adenoviral vector expressing β-galactosidase (Adβgal). After irradiation of the cells, syngeneic 129/Sv mice were vaccinated three times at weekly intervals. After 3 weeks, they were challenged with orthotopic 178-2 BMA cells. After 21 days, fewer than 60% of the RTVP-1-cell-vaccinated mice developed tumors compared to 100% of the control mice. The RTVP-1-cell vaccine significantly reduced primary tumor wet weight compared with control Adβgal-cell vaccine (P

AB - We previously identified a novel p53 target gene, RTVP-1, that possesses unique cytotoxic and immunostimulatory activities which make it potentially useful for cancer gene therapy. To test the therapeutic potential of RTVP-1 in a gene-modified tumor cell-based vaccine model, we used an adenoviral vector capable of efficient transduction and expression of RTVP-1 (AdRTVP-1), together with a highly metastatic mouse prostate cancer cell line (178-2 BMA). A vaccine was prepared with 178-2 BMA cells transduced with AdRTVP-1 or a control adenoviral vector expressing β-galactosidase (Adβgal). After irradiation of the cells, syngeneic 129/Sv mice were vaccinated three times at weekly intervals. After 3 weeks, they were challenged with orthotopic 178-2 BMA cells. After 21 days, fewer than 60% of the RTVP-1-cell-vaccinated mice developed tumors compared to 100% of the control mice. The RTVP-1-cell vaccine significantly reduced primary tumor wet weight compared with control Adβgal-cell vaccine (P

KW - Immunotherapy

KW - Orthotopic

KW - Prostate cancer

KW - RTVP-1

KW - Vaccine

UR - http://www.scopus.com/inward/record.url?scp=33747606233&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33747606233&partnerID=8YFLogxK

U2 - 10.1038/sj.cgt.7700919

DO - 10.1038/sj.cgt.7700919

M3 - Article

C2 - 16485011

AN - SCOPUS:33747606233

VL - 13

SP - 658

EP - 663

JO - Cancer Gene Therapy

JF - Cancer Gene Therapy

SN - 0929-1903

IS - 7

ER -